Sanofi has announced the appointment of Jean-Paul Kress as an independent director to its Board, effective January 1, 2025. Kress, with over 30 years of experience in the pharmaceutical industry, ...

Sanofi (SNYNF, SNY) and SK bioscience have entered an expanded agreement to develop, license and commercialize next-generation ...

Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.

Sanofi is joining its fellow drugmakers in trying to put new restrictions on savings sent to hospitals in a federal drug discount program. A spokesperson for Sanofi confirmed plans to implement a ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to the cardiovascular candidate. The rights will be transferred from ...

Sanofi estimates that the annual cost for a typical patient will be around $280,000 per year before discounts or rebates, in line with other drugs used to treat rare, chronic diseases.

Copyright © 2024 MarketWatch, Inc. All rights reserved.